Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 14/20 | 0.74 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.74 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.67 |
| ▸ | MDH2 | P40926 | 2/20 | 0.57 |
| ▸ | MDH1 | P40925 | 1/20 | 0.57 |
| ▸ | EP300 | Q09472 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418072 | 0.90 | HIF1A (0.66) | HIF1AEPAS1SERPINE1MDH2MDH1 | |
| SCHEMBL416528 | 0.90 | SERPINE1 (0.65) | HIF1AEPAS1SERPINE1MDH2MDH1 | |
| SCHEMBL23086145 | 0.89 | SERPINE1 (0.64) | HIF1AEPAS1SERPINE1MDH2MDH1 | |
| SCHEMBL418066 | 0.89 | SERPINE1 (0.64) | HIF1AEPAS1SERPINE1MDH2MDH1 | |
| SCHEMBL420870 | 0.89 | SERPINE1 (0.66) | HIF1AEPAS1SERPINE1RAB9ATHRB | |
| SCHEMBL29896966 | 0.89 | SERPINE1 (0.66) | HIF1AEPAS1SERPINE1RAB9ATHRB | |
| SCHEMBL4293719 | 0.85 | HIF1A (1.00) | HIF1AEPAS1MDH2MDH1EP300 | |
| SCHEMBL4297107 | 0.83 | HIF1A (0.67) | HIF1AEPAS1SERPINE1MDH2MDH1 | |
| SCHEMBL419275 | 0.82 | HIF1A (0.66) | HIF1AEPAS1SERPINE1MDH2MDH1 | |
| SCHEMBL458286 | 0.82 | SERPINE1 (0.59) | HIF1AEPAS1SERPINE1MDH2MDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4039276-A1 | INHIBITOR AGAINST EXPRESSION OF IMMUNE CHECKPOINT MOLECULE | Renascience Inc. (JP) | 2022-08-10 | — | — | EP | disclosed |
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| EP-2990057-B1 | PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT | RENASCIENCE CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-10092537-B2 | Use for PAI-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2018-10-09 | — | — | US | disclosed |
| US-20160158188-A1 | NOVEL USE FOR PAI-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-2990057-A1 | NOVEL USE FOR PAI-1 INHIBITOR | Renascience Co., Ltd. (JP) | 2016-03-02 | — | — | EP | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158188-A1 | NOVEL USE FOR PAI-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | HIF1A 190/4885EPAS1 133/4885SERPINE1 1/4885 |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | HIF1A 561/4885EPAS1 256/4885SERPINE1 1/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | HIF1A 561/4885EPAS1 256/4885SERPINE1 1/4885 |
| US-10092537-B2 | Use for PAI-1 inhibitor | SERPINE1, SERPINC1, SERPINB1 | HIF1A 183/4885EPAS1 153/4885SERPINE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.